Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (437) 437
life sciences & biomedicine (421) 421
humans (414) 414
gastroenterology & hepatology (281) 281
male (269) 269
female (265) 265
adult (244) 244
middle aged (234) 234
biological and medical sciences (180) 180
medical sciences (177) 177
antiviral agents - therapeutic use (166) 166
infectious diseases (157) 157
viral diseases (116) 116
viral hepatitis (115) 115
human viral diseases (113) 113
treatment outcome (111) 111
hepatitis c, chronic - drug therapy (110) 110
drug therapy, combination (109) 109
hepatitis c (107) 107
interferon-alpha - therapeutic use (107) 107
aged (106) 106
hepacivirus - genetics (100) 100
hepatitis b (95) 95
gastroenterology and hepatology (94) 94
genotype (94) 94
hepatitis (90) 90
hepatitis b, chronic - drug therapy (90) 90
hepatitis c virus (90) 90
recombinant proteins (89) 89
abridged index medicus (85) 85
antiviral agents (83) 83
interferon (81) 81
pharmacology. drug treatments (73) 73
hepatitis c, chronic - virology (68) 68
health aspects (65) 65
life sciences (65) 65
antiviral agents - administration & dosage (63) 63
hepatitis b virus - genetics (62) 62
polyethylene glycols - therapeutic use (62) 62
ribavirin - therapeutic use (61) 61
rna, viral - blood (61) 61
microbiology (60) 60
antiviral agents - adverse effects (58) 58
gastroenterology. liver. pancreas. abdomen (57) 57
ribavirin (56) 56
alanine transaminase - blood (55) 55
adolescent (52) 52
prospective studies (52) 52
dna, viral - blood (51) 51
viral load (51) 51
liver - pathology (50) 50
antibiotics. antiinfectious agents. antiparasitic agents (49) 49
virology (48) 48
care and treatment (47) 47
cirrhosis (47) 47
drug therapy (47) 47
interferon-alpha - administration & dosage (45) 45
liver (44) 44
adenine - analogs & derivatives (42) 42
time factors (40) 40
biological response modifiers (39) 39
chemistry (39) 39
hepacivirus - drug effects (39) 39
hepatitis b virus (39) 39
interferon-alpha - adverse effects (39) 39
hepatitis b e antigens - blood (38) 38
hepatitis b, chronic - virology (38) 38
hepatitis c - drug therapy (38) 38
hepatology (38) 38
retrospective studies (38) 38
ribavirin - administration & dosage (38) 38
analysis (37) 37
liver cirrhosis - virology (37) 37
metallurgy (37) 37
biochemistry (36) 36
hepatitis c, chronic - pathology (36) 36
liver cirrhosis (36) 36
polyethylene glycols - administration & dosage (36) 36
young adult (36) 36
adenine - therapeutic use (35) 35
double-blind method (35) 35
follow-up studies (35) 35
hepatitis b virus - drug effects (35) 35
patients (34) 34
tenofovir (34) 34
virus diseases (34) 34
enzymology (33) 33
fibrosis (33) 33
general & internal medicine (33) 33
hepatitis b surface antigens - blood (33) 33
hepatitis c, chronic - complications (33) 33
liver. biliary tract. portal circulation. exocrine pancreas (33) 33
medicine, general & internal (33) 33
prognosis (33) 33
recombinant proteins - therapeutic use (33) 33
wine (33) 33
beer (32) 32
compositions or test papers therefor (32) 32
condition-responsive control in microbiological orenzymological processes (32) 32
genetic aspects (32) 32
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (779) 779
French (90) 90
German (10) 10
Korean (8) 8
Danish (1) 1
Norwegian (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Hepatitis B and hepatitis C in 2009
by Marcellin, Patrick
Liver international, ISSN 1478-3223, 01/2009, Volume 29, Issue 1, pp. 1 - 8
Antiviral therapy | cirrhosis | hepatocellular carcinoma | Cirrhosis | Hepatocellular carcinoma | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepatitis B - physiopathology | Global Health | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Hepatitis C - epidemiology | Humans | Hepatitis B - drug therapy | Hepatitis B - epidemiology | Hepatitis C - physiopathology | Liver cancer | Antiviral agents | Transplantation of organs, tissues, etc | Hepatitis C | Health aspects | Public health | Hepatitis B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening
by Marcellin, Patrick and Kutala, Blaise K
Liver international, ISSN 1478-3223, 02/2018, Volume 38, Issue S1, pp. 2 - 6
epidemiology | alcoholic liver disease | NAFLD | screening | hepatitis B | hepatitis C | ALT | chronic liver disease | NASH | cirrhosis | hepatocellular carcinoma | Hepatitis C | Epidemiology | Liver cirrhosis | Public health | Medical personnel | Health care | Cirrhosis | Screening | Liver diseases | Liver | Viruses | Morbidity | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow
by Asselah, Tarik and Marcellin, Patrick
Liver international, ISSN 1478-3223, 02/2012, Volume 32, Issue 1, pp. 88 - 102
boceprevir | ribavirin | NS5A inhibitors | telaprevir | polymerase inhibitors | protease inhibitors | pegylated interferon | Boceprevir | Protease inhibitors | Pegylated interferon | Polymerase inhibitors | Telaprevir | Ribavirin | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Serine Proteinase Inhibitors - administration & dosage | Disease Eradication | Drug Administration Schedule | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Proline - therapeutic use | Time Factors | Drug Resistance, Viral - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text New direct‐acting antivirals' combination for the treatment of chronic hepatitis C
by Asselah, Tarik and Marcellin, Patrick
Liver international, ISSN 1478-3223, 01/2011, Volume 31, Issue 1, pp. 68 - 77
boceprevir | interferon‐λ | ribavirin | telaprevir | polymerase inhibitors | protease inhibitors | pegylated interferon | IL‐28B | Boceprevir | Protease inhibitors | Pegylated interferon | IL-28B | Polymerase inhibitors | Telaprevir | Interferon-λ | Ribavirin | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Polyethylene Glycols - metabolism | Interferon-alpha - metabolism | Virus Replication - drug effects | Proline - analogs & derivatives | Standard of Care | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Proline - therapeutic use | Drug Therapy, Combination - methods | Signal Transduction - drug effects | Hepatitis C, Chronic - genetics | Protease Inhibitors - therapeutic use | Liver cancer | Proteases | Biological response modifiers | Hepatitis C | Drug therapy | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Viral hepatitis: towards the eradication of HCV and a cure for HBV
by Marcellin, Patrick
Liver international, ISSN 1478-3223, 01/2016, Volume 36, Issue S1, pp. 5 - 6
Disease Eradication - trends | Congresses as Topic | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Hepatitis C - epidemiology | Humans | Hepatitis B - drug therapy | Drug Therapy, Combination | Paris | Hepatitis C virus | Control | Hepatitis B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Interferon free therapy with direct acting antivirals for HCV
by Asselah, Tarik and Marcellin, Patrick
Liver international, ISSN 1478-3223, 02/2013, Volume 33, Issue 1, pp. 93 - 104
sofosbuvir | faldaprevir | simeprevir | ribavirin | NS5A inhibitors | NS5B polymerase inhibitors | protease inhibitors | asunaprevir | daclatasvir | Daclatasvir | Simeprevir | Protease inhibitors | Faldaprevir | Asunaprevir | Ribavirin | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Recombinant Proteins - therapeutic use | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Models, Molecular | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Hepacivirus - enzymology | Serine Proteinase Inhibitors - chemistry | Antiviral Agents - chemistry | Serine Proteinase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Drug Design | Molecular Structure | Drug Therapy, Combination | Viral Nonstructural Proteins - antagonists & inhibitors | Interferon | Biological response modifiers | Hepatitis C virus | Proteases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
by Marcellin, Patrick, Prof and Gane, Edward, Prof and Buti, Maria, Prof and Afdhal, Nezam, Prof and Sievert, William, Prof and Jacobson, Ira M, Prof and Washington, Mary Kay, Prof and Germanidis, George, Prof and Flaherty, John F, PharmD and Schall, Raul Aguilar, PhD and Bornstein, Jeffrey D, MD and Kitrinos, Kathryn M, PhD and Subramanian, G Mani, MD and McHutchison, John G, MD and Heathcote, E Jenny, Prof
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9865, pp. 468 - 475
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | General aspects | Viral hepatitis | Infectious diseases | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Other diseases. Semiology | Immunohistochemistry | Severity of Illness Index | Adenine - analogs & derivatives | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Safety Management | Male | Treatment Outcome | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - administration & dosage | Dose-Response Relationship, Drug | Tenofovir | Hepatitis B virus - drug effects | Organophosphonates - administration & dosage | Hepatitis B, Chronic - drug therapy | Time Factors | Adult | Female | Biopsy, Needle | Hepatitis B, Chronic - pathology | Complications and side effects | Dosage and administration | Research | Drug therapy | Liver cirrhosis | Risk factors | Hepatitis B | Hepatitis | Liver cancer | Consent | Mortality | Infections | Histology | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Second‐wave IFN‐based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir
by Asselah, Tarik and Marcellin, Patrick
Liver international, ISSN 1478-3223, 02/2014, Volume 34, Issue 1, pp. 60 - 68
antiviral potency | direct‐acting antivirals | pills burden | safety | resistance | Resistance | Safety | Antiviral potency | Direct-acting antivirals | Pills burden | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Simeprevir | Antiviral Agents - pharmacology | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Hepacivirus - genetics | Genotype | Clinical Trials as Topic | Drug Approval | Sulfonamides - pharmacology | Uridine Monophosphate - pharmacology | Drug Therapy, Combination - adverse effects | Drug Therapy, Combination - methods | Drug Therapy, Combination - trends | Time Factors | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Thiazoles - pharmacology | Oligopeptides - pharmacology | Sofosbuvir | Genetic aspects | Interferon | Hepatitis C virus | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?
by Asselah, Tarik and Marcellin, Patrick and Schinazi, Raymond F
Liver international, ISSN 1478-3223, 02/2018, Volume 38, Issue S1, pp. 7 - 13
screening | HCV elimination | compliance | chronic hepatitis C | people who inject drugs | genotype | Virus diseases | Antiviral agents | Hepatitis C virus | Drug therapy | Health aspects | Hepatitis | Viruses | Interferon | Infections | Hepatitis C | Drug development
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
by Manns, Michael, Prof and Marcellin, Patrick, Prof and Poordad, Fred, Prof and de Araujo, Evaldo Stanislau Affonso, PhD and Buti, Maria, Prof and Horsmans, Yves, Prof and Janczewska, Ewa, MD and Villamil, Federico, Prof and Scott, Jane, PhD and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 414 - 426
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Methods | Ribavirin | Analysis | Clinical trials | Genetic aspects | Interferon | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights